GlassScriptPhysician profile
Arnel H Panelo
NPI 1447229935
$4,967.47
in general payments reported to CMS, 2019-2025
22 companies · $270 in 2025
The $270 reported for 2025 was more than what 82% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $867 · 2020: $746 · 2021: $1,100 · 2022: $921 · 2023: $179 · 2024: $884 · 2025: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,333.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,100.10 | 2019-2024 | Xarelto |
| Pfizer INC. | $948.23 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $531.77 | 2019-2025 | Lokelma, Andexxa |
| Novartis Pharmaceuticals Corporation | $500.89 | 2019-2024 | |
| Gilead Sciences, INC. | $302.37 | 2022-2024 | Veklury |
| E.R. Squibb & Sons, L.L.C. | $237.86 | 2019-2024 | Eliquis |
| Merck Sharp & Dohme LLC | $171.66 | 2021-2024 | Dificid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $171.17 | 2019-2021 | |
| Abbvie INC. | $159.50 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $141.69 | 2022-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $136.54 | 2019-2020 | |
| Portola Pharmaceuticals, LLC | $135.57 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $126.16 | 2019 | |
| Alexion Pharmaceuticals, INC. | $83.06 | 2021-2024 | Ultomiris |
| Mylan Specialty L.P. | $53.63 | 2020-2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $41.66 | 2022-2025 | Ozempic, Rybelsus |
| Abiomed | $32.48 | 2021 | |
| Vifor Pharma, INC. | $28.87 | 2019 | |
| Bioxcel Therapeutics, INC. | $20.36 | 2023 | Igalmi |
| Inari Medical, INC. | $17.75 | 2021 | |
| Csl Behring | $14.75 | 2019 | |
| Strongbridge US INC. | $11.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arnel Panelo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.